Covetrus Inc (NASDAQ:CVET) CEO Benjamin Shaw bought 1,800 shares of the company’s stock in a transaction dated Wednesday, August 21st. The shares were purchased at an average price of $13.87 per share, with a total value of $24,966.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

CVET stock traded up $0.54 during trading on Thursday, reaching $14.34. The company had a trading volume of 20,761 shares, compared to its average volume of 2,436,123. Covetrus Inc has a 52 week low of $12.22 and a 52 week high of $43.83. The business’s 50 day moving average price is $22.41. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.74 and a quick ratio of 0.91.

Covetrus (NASDAQ:CVET) last released its quarterly earnings results on Tuesday, August 13th. The company reported $0.12 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.16 by ($0.04). The company had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1.05 billion. On average, equities research analysts expect that Covetrus Inc will post 0.4 earnings per share for the current fiscal year.

An institutional investor recently bought a new position in Covetrus stock. Gamble Jones Investment Counsel purchased a new position in Covetrus Inc (NASDAQ:CVET) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 77,986 shares of the company’s stock, valued at approximately $1,908,000. Gamble Jones Investment Counsel owned approximately 0.07% of Covetrus at the end of the most recent reporting period. 75.10% of the stock is owned by hedge funds and other institutional investors.

CVET has been the subject of a number of analyst reports. ValuEngine lowered shares of Covetrus from a “buy” rating to a “hold” rating in a report on Tuesday, August 13th. Raymond James decreased their price target on shares of Covetrus from $45.00 to $21.00 and set an “outperform” rating for the company in a research note on Thursday, August 15th. Guggenheim began coverage on shares of Covetrus in a research note on Thursday, May 23rd. They issued a “neutral” rating for the company. Stifel Nicolaus decreased their price target on shares of Covetrus from $30.00 to $18.00 and set a “hold” rating for the company in a research note on Wednesday, August 14th. Finally, Credit Suisse Group set a $15.00 price target on shares of Covetrus and gave the stock a “hold” rating in a research note on Friday, August 16th. Six research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $20.75.

Covetrus Company Profile

Covetrus, Inc engages in developing technologies and services for animal health industry. It also provides products, software, and services to help drive improved patient health, strong client relationships, and successful financial outcomes for veterinary professionals. The company was founded on April 13, 2018 and is headquartered in Melville, NY.

Read More: What is the Rule of 72?

Receive News & Ratings for Covetrus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Covetrus and related companies with's FREE daily email newsletter.